IP Library › Granted Patent US 12,440,262
Granted Patent B2
US 12,440,262 · App. 18/338,594 · Granted Oct 14, 2025

Power-controlled waveform in electrosurgical systems

Inventors: Kester Julian Batchelor (Mound, MN); Maureen D. Busche (Cokato, MN); Wayne Williams (Penarth, GB)
Assignee: Gyrus ACMI, Inc.
A61B18/1233A61B18/1445A61B2017/00017A61B2018/00589A61B2018/0063A61B2018/00642A61B2018/00648A61B2018/00666A61B2018/00678A61B2018/00684A61B2018/00702A61B2018/00708A61B2018/0072A61B2018/00755A61B2018/00761A61B2018/00779A61B2018/00791A61B2018/00827A61B2018/00875A61B2018/00886A61B2018/00898A61B2018/00928A61B2018/00994A61B18/1206A61B18/1442
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,440,262
App. No.
18/338,594
Granted
Oct 14, 2025
Kind
B2
Abstract

Apparatus and associated methods relate to controlling electrical power of an electrotherapeutic signal that is provided to a biological tissue engaged by an electrosurgical instrument during a medical procedure. Electrical power—a product of a voltage difference across and an electrical current conducted by the engaged biological tissue—is controlled according to a therapeutic schedule. The electrotherapeutic schedule can be reduced or terminated in response to a termination criterion being met. In some examples, the termination criterion is a current characteristic, such as, for example, a decrease in current conducted by the engaged biological tissue. In some examples, the termination criterion is a biological tissue resistance characteristic, such as, for example, an increase in the biological tissue resistance that exceeds a predetermined delta resistance value.

Claims (37)

1. A surgical generator configured to generate and provide controlled electrical power of a therapeutic signal to biological tissue in electrical communication with an instrument, the surgical generator comprising:

a control circuit in communication with an electrical-energy source, the electrical-energy source electrically coupled to the instrument and configured to generate the therapeutic signal, the control circuit configured to:

control the electrical power of the therapeutic signal provided to the biological tissue during a portion of a non-sealing therapeutic phase according to a therapeutic plan by increasing the electrical power as a function of resistance, wherein the electrical power decreases to a non-zero level between the non-sealing therapeutic phase and a subsequent therapeutic phase.

2. The surgical generator of claim 1 , wherein the control circuit is configured to:

control a voltage of the therapeutic signal provided to the biological tissue during a portion of a drying phase according to the therapeutic plan.

3. The surgical generator of claim 2 , wherein the control circuit is configured to:

monitor the voltage of the therapeutic signal; and

maintain the voltage when the voltage meets a voltage threshold.

4. The surgical generator of claim 1 , wherein the control circuit is configured to:

control the electrical power of the therapeutic signal provided to the biological tissue during the portion of the therapeutic phase using a pre-defined power curve.

5. The surgical generator of claim 4 , wherein the pre-defined power curve includes a linear portion.

6. The surgical generator of claim 4 , wherein the pre-defined power curve includes two or more linear portions.

7. A method of delivering controlled electrical power of a therapeutic signal to biological tissue in electrical communication with an instrument, the method comprising:

generating, using an electrical-energy source electrically coupled to the instrument, the therapeutic signal; and

controlling the electrical power of the therapeutic signal provided to the biological tissue during a portion of a non-sealing therapeutic phase according to a therapeutic plan by increasing the electrical power as a function of resistance or current, wherein the electrical power decreases to a non-zero level between the non-sealing therapeutic phase and a subsequent therapeutic phase.

8. The method of claim 7 , comprising:

controlling a voltage of the therapeutic signal provided to the biological tissue during a portion of a drying phase according to the therapeutic plan.

9. The method of claim 8 , comprising:

monitoring the voltage of the therapeutic signal; and

maintaining the voltage when the voltage meets a voltage threshold.

10. The method of claim 7 , comprising:

controlling the electrical power of the therapeutic signal provided to the biological tissue during the portion of the therapeutic phase using a pre-defined power curve.

11. The method of claim 10 , wherein the pre-defined power curve includes a linear portion.

12. The method of claim 11 , wherein the pre-defined power curve includes two or more linear portions.

13. The method of claim 11 , wherein controlling the electrical power of the therapeutic signal provided to the biological tissue during the portion of the non-sealing therapeutic phase according to the therapeutic plan by increasing the electrical power as a function of resistance or current includes:

controlling the electrical power of the therapeutic signal provided to the biological tissue during the portion of the non-sealing therapeutic phase according to the therapeutic plan by increasing the electrical power as a function of current.

14. The method of claim 13 , wherein the function of current is a function of an instantaneous measured change in current.

15. The method of claim 14 , wherein the function of the instantaneous measured change in current is a linear function.

16. The method of claim 11 , wherein controlling the electrical power of the therapeutic signal provided to the biological tissue during the portion of the non-sealing therapeutic phase according to the therapeutic plan by increasing the electrical power as a function of resistance or current includes:

controlling the electrical power of the therapeutic signal provided to the biological tissue during the portion of the non-sealing therapeutic phase according to the therapeutic plan by increasing the electrical power as a function of resistance.

17. A surgical generator configured to generate and provide controlled electrical power of a therapeutic signal to biological tissue in electrical communication with an instrument, the surgical generator comprising:

a control circuit in communication with an electrical-energy source, the electrical-energy source electrically coupled to the instrument and configured to generate the therapeutic signal, the control circuit configured to:

control the electrical power of the therapeutic signal provided to the biological tissue during a portion of a non-sealing therapeutic phase according to a therapeutic plan by increasing the electrical power as a function of current, wherein the electrical power decreases to a non-zero level between the non-sealing therapeutic phase and a subsequent therapeutic phase.

18. The surgical generator of claim 17 , wherein the function of current is a function of an instantaneous measured change in current.

19. The surgical generator of claim 17 , comprising:

controlling the electrical power of the therapeutic signal provided to the biological tissue during the portion of the therapeutic phase using a pre-defined power curve.

20. The surgical generator of claim 19 , wherein the pre-defined power curve includes a linear portion.

Assignments (4)
CONFIRMATORY ASSIGNMENT Recorded Sep 27, 2023
From: BATCHELOR, KESTER JULIAN
To: GYRUS ACMI, INC. D/B/A OLYMPUS SURGICAL TECHNOLOGIES AMERICA
Reel/Frame 065043/0814 →
CONFIRMATORY ASSIGNMENT Recorded Sep 27, 2023
From: BUSCHE, MAUREEN D.
To: GYRUS ACMI, INC. D/B/A OLYMPUS SURGICAL TECHNOLOGIES AMERICA
Reel/Frame 065043/0853 →
CONFIRMATORY ASSIGNMENT Recorded Sep 27, 2023
From: WILLIAMS, WAYNE
To: GYRUS MEDICAL LIMITED
Reel/Frame 065043/0952 →
CONFIRMATORY ASSIGNMENT Recorded Sep 27, 2023
From: GYRUS MEDICAL LIMITED
To: GYRUS ACMI, INC. D/B/A OLYMPUS SURGICAL TECHNOLOGIES AMERICA
Reel/Frame 065045/0494 →
Continuity (9)
Continuation 16874185 · May 14, 2020
Continuation PCTUS2020031857 · May 7, 2020
Provisional Application 62905318 · Sep 24, 2019
Provisional Application 62905360 · Sep 24, 2019
Provisional Application 62905366 · Sep 24, 2019
Provisional Application 62905337 · Sep 24, 2019
Provisional Application 62905345 · Sep 24, 2019
Provisional Application 62845647 · May 9, 2019
Related Publication 20240000495A1 · Jan 4, 2024
References Cited (400)
US 5372596A · Klicek et al. · 1994 [cited by applicant]
US 5540684A · Hassler, Jr. · 1996 [cited by applicant]
US 5558671A · Yates · 1996 [cited by applicant]
US 5769849A · Eggers · 1998 [cited by applicant]
US 5830212A · Cartmell et al. · 1998 [cited by applicant]
US 6261286B1 · Goble et al. · 2001 [cited by applicant]
US 6398779B1 · Buysse et al. · 2002 [cited by applicant]
US 6402742B1 · Blewett et al. · 2002 [cited by applicant]
US 6423057B1 · He et al. · 2002 [cited by applicant]
US 6468271B1 · Wentzel et al. · 2002 [cited by applicant]
US 6648883B2 · Francischelli et al. · 2003 [cited by applicant]
US 6740079B1 · Eggers et al. · 2004 [cited by applicant]
US 6790206B2 · Panescu · 2004 [cited by applicant]
US 6796981B2 · Wham et al. · 2004 [cited by applicant]
US 6830569B2 · Thompson et al. · 2004 [cited by applicant]
US 6855141B2 · Lovewell · 2005 [cited by applicant]
US 6942660B2 · Pantera et al. · 2005 [cited by applicant]
US 6948503B2 · Refior et al. · 2005 [cited by applicant]
US 6958064B2 · Rioux et al. · 2005 [cited by applicant]
US 6962587B2 · Johnson et al. · 2005 [cited by applicant]
US 7037306B2 · Podany et al. · 2006 [cited by applicant]
US 7041096B2 · Malis et al. · 2006 [cited by applicant]
US 7074218B2 · Washington et al. · 2006 [cited by applicant]
US 7282049B2 · Orszulak et al. · 2007 [cited by applicant]
US 7364577B2 · Wham et al. · 2008 [cited by applicant]
US 7566332B2 · Jarrard et al. · 2009 [cited by applicant]
US 7582084B2 · Swanson et al. · 2009 [cited by applicant]
US 7601149B2 · Dicarlo et al. · 2009 [cited by applicant]
US 7680543B2 · Azure · 2010 [cited by applicant]
US 7722601B2 · Wham et al. · 2010 [cited by applicant]
US 7824399B2 · Francischelli et al. · 2010 [cited by applicant]
US 7901400B2 · Wham et al. · 2011 [cited by applicant]
US 7942874B2 · Eder et al. · 2011 [cited by applicant]
US 7972328B2 · Wham et al. · 2011 [cited by applicant]
US 7972334B2 · Mcgreevy et al. · 2011 [cited by applicant]
US 8105323B2 · Buysse et al. · 2012 [cited by applicant]
US 8147485B2 · Wham et al. · 2012 [cited by applicant]
US 8152800B2 · Behnke · 2012 [cited by applicant]
US 8152801B2 · Goldberg et al. · 2012 [cited by applicant]
US 8162932B2 · Podhajsky et al. · 2012 [cited by applicant]
US 8167875B2 · Podhajsky et al. · 2012 [cited by applicant]
US 8187263B2 · Behnke et al. · 2012 [cited by applicant]
US 8211100B2 · Podhajsky et al. · 2012 [cited by applicant]
US 8216223B2 · Wham et al. · 2012 [cited by applicant]
US 8231616B2 · Mcpherson et al. · 2012 [cited by applicant]
US 8241275B2 · Hong et al. · 2012 [cited by applicant]
US 8257350B2 · Marion · 2012 [cited by applicant]
US 8287528B2 · Wham et al. · 2012 [cited by applicant]
US 8290578B2 · Schneider · 2012 [cited by applicant]
US 8317783B2 · Cao et al. · 2012 [cited by applicant]
US 8333759B2 · Podhajsky · 2012 [cited by applicant]
US 8382751B2 · Gilbert et al. · 2013 [cited by applicant]
US 8394092B2 · Brannan · 2013 [cited by applicant]
US 8419727B2 · Koss et al. · 2013 [cited by applicant]
US 8485993B2 · Orszulak et al. · 2013 [cited by applicant]
US 8500727B2 · Aramayo · 2013 [cited by applicant]
US 8556891B2 · Mathur · 2013 [cited by applicant]
US 8556892B2 · Stewart et al. · 2013 [cited by applicant]
US 8591506B2 · Wham et al. · 2013 [cited by applicant]
US 8617154B2 · Johnston · 2013 [cited by applicant]
US 8647340B2 · Blaha · 2014 [cited by applicant]
US 8663214B2 · Weinberg et al. · 2014 [cited by applicant]
US 8685016B2 · Wham et al. · 2014 [cited by applicant]
US 8702690B2 · Paul et al. · 2014 [cited by applicant]
US 8728139B2 · Azure et al. · 2014 [cited by applicant]
US 8771269B2 · Sherman et al. · 2014 [cited by applicant]
US 8795270B2 · Drake · 2014 [cited by applicant]
US 8827992B2 · Koss et al. · 2014 [cited by applicant]
US 8852179B2 · Ward et al. · 2014 [cited by applicant]
US 8858471B2 · Barthe · 2014 [cited by applicant]
US 8915911B2 · Azure · 2014 [cited by applicant]
US 8920421B2 · Rupp · 2014 [cited by applicant]
US 8926605B2 · McCarthy et al. · 2015 [cited by applicant]
US 8961506B2 · McCarthy et al. · 2015 [cited by applicant]
US 8968297B2 · Collins · 2015 [cited by applicant]
US 8986296B2 · Peyman · 2015 [cited by applicant]
US 9011337B2 · Slayton et al. · 2015 [cited by applicant]
US 9011424B2 · Werner · 2015 [cited by applicant]
US 9014814B2 · McCarthy et al. · 2015 [cited by applicant]
US 9017326B2 · Dinardo et al. · 2015 [cited by applicant]
US 9028482B2 · Collins · 2015 [cited by applicant]
US 9037447B2 · Heckel · 2015 [cited by applicant]
US 9044238B2 · Orszulak · 2015 [cited by applicant]
US 9055951B2 · Deshpande · 2015 [cited by applicant]
US 9072532B2 · Van Der Weide et al. · 2015 [cited by applicant]
US 9095350B2 · Condie et al. · 2015 [cited by applicant]
US 9125658B2 · Schall · 2015 [cited by applicant]
US 9161813B2 · Benamou · 2015 [cited by applicant]
US 9168083B2 · Schall et al. · 2015 [cited by applicant]
US 9186200B2 · Unger et al. · 2015 [cited by applicant]
US 9204921B2 · Sisken · 2015 [cited by applicant]
US 9232974B2 · Dycus et al. · 2016 [cited by applicant]
US 9277962B2 · Koss et al. · 2016 [cited by applicant]
US 9314291B2 · Schall et al. · 2016 [cited by applicant]
US 9375250B2 · Krapohl · 2016 [cited by applicant]
US 9375270B2 · Wham et al. · 2016 [cited by applicant]
US 9375271B2 · Wham et al. · 2016 [cited by applicant]
US 9463067B2 · Wham et al. · 2016 [cited by applicant]
US 9681883B2 · Windgassen et al. · 2017 [cited by applicant]
US 10285750B2 · Coulson et al. · 2019 [cited by applicant]
US 10512499B2 · Mchenry et al. · 2019 [cited by applicant]
US 11666372B2 · Batchelor et al. · 2023 [cited by applicant]
US 11672588B2 · Batchelor et al. · 2023 [cited by applicant]
US 11723711B2 · Batchelor · 2023 [cited by examiner]
US 11751933B2 · Batchelor et al. · 2023 [cited by applicant]
US 11819258B2 · Batchelor et al. · 2023 [cited by applicant]
US 11864726B2 · Batchelor et al. · 2024 [cited by applicant]
US 11864813B2 · Batchelor et al. · 2024 [cited by applicant]
US 11877787B2 · Batchelor et al. · 2024 [cited by applicant]
US 11883088B2 · Batchelor et al. · 2024 [cited by applicant]
US 11918274B2 · Batchelor et al. · 2024 [cited by applicant]
US 12059191B2 · Batchelor et al. · 2024 [cited by applicant]
US 12070259B2 · Batchelor · 2024 [cited by applicant]
US 12161384B2 · Batchelor et al. · 2024 [cited by applicant]
US 12171480B2 · Batchelor et al. · 2024 [cited by applicant]
US 12193721B2 · Batchelor et al. · 2025 [cited by applicant]
US 12303183B2 · Batchelor et al. · 2025 [cited by applicant]
US 20010039417A1 · Harano et al. · 2001 [cited by applicant]
US 20020165531A1 · Goble · 2002 [cited by applicant]
US 20030130711A1 · Pearson et al. · 2003 [cited by applicant]
US 20040097914A1 · Pantera et al. · 2004 [cited by applicant]
US 20040167508A1 · Wham et al. · 2004 [cited by applicant]
US 20050033278A1 · McClurken et al. · 2005 [cited by applicant]
US 20050101947A1 · Jarrard et al. · 2005 [cited by applicant]
US 20070173806A1 · Orszulak et al. · 2007 [cited by applicant]
US 20070173811A1 · Couture · 2007 [cited by examiner]
US 20070282320A1 · Buysse et al. · 2007 [cited by applicant]
US 20080114351A1 · Irisawa et al. · 2008 [cited by applicant]
US 20090048595A1 · Mihori et al. · 2009 [cited by applicant]
US 20100094276A1 · Kabaya et al. · 2010 [cited by applicant]
US 20100160725A1 · Kiser et al. · 2010 [cited by applicant]
US 20110087217A1 · Yates et al. · 2011 [cited by applicant]
US 20110118736A1 · Harper et al. · 2011 [cited by applicant]
US 20110238056A1 · Koss et al. · 2011 [cited by applicant]
US 20120150169A1 · Zielinksi et al. · 2012 [cited by applicant]
US 20130197503A1 · Orszulak · 2013 [cited by applicant]
US 20130267947A1 · Orszulak · 2013 [cited by applicant]
US 20130338467A1 · Grasse et al. · 2013 [cited by applicant]
US 20140025061A1 · Benamou · 2014 [cited by applicant]
US 20140350548A1 · Schall et al. · 2014 [cited by applicant]
US 20150272657A1 · Yates et al. · 2015 [cited by applicant]
US 20150320478A1 · Cosman, Jr. et al. · 2015 [cited by applicant]
US 20150320481A1 · Cosman, Jr. et al. · 2015 [cited by applicant]
US 20160000495A1 · Elliott et al. · 2016 [cited by applicant]
US 20160045248A1 · Unger et al. · 2016 [cited by applicant]
US 20160058492A1 · Yates et al. · 2016 [cited by applicant]
US 20170000542A1 · Yates et al. · 2017 [cited by applicant]
US 20170000553A1 · Wiener et al. · 2017 [cited by applicant]
US 20170000554A1 · Yates et al. · 2017 [cited by applicant]
US 20170027633A1 · Wham et al. · 2017 [cited by applicant]
US 20170196579A1 · Batchelor et al. · 2017 [cited by applicant]
US 20170215936A1 · Wallace · 2017 [cited by applicant]
US 20170333110A1 · Keller et al. · 2017 [cited by applicant]
US 20170333111A1 · Kabaya et al. · 2017 [cited by applicant]
US 20180250063A1 · Schall et al. · 2018 [cited by applicant]
US 20180280071A1 · Nold et al. · 2018 [cited by applicant]
US 20180333185A1 · Asher et al. · 2018 [cited by applicant]
US 20180333189A1 · Asher et al. · 2018 [cited by applicant]
US 20190200998A1 · Shelton, IV et al. · 2019 [cited by applicant]
US 20190201044A1 · Shelton, IV et al. · 2019 [cited by applicant]
US 20200046402A1 · Houser · 2020 [cited by applicant]
US 20200352618A1 · Batchelor · 2020 [cited by applicant]
US 20200352624A1 · Batchelor et al. · 2020 [cited by applicant]
US 20200352625A1 · Batchelor et al. · 2020 [cited by applicant]
US 20200352626A1 · Batchelor et al. · 2020 [cited by applicant]
US 20200352627A1 · Batchelor et al. · 2020 [cited by applicant]
US 20200352628A1 · Batchelor et al. · 2020 [cited by applicant]
US 20200352629A1 · Batchelor et al. · 2020 [cited by applicant]
US 20200352630A1 · Batchelor et al. · 2020 [cited by applicant]
US 20200352631A1 · Batchelor et al. · 2020 [cited by applicant]
US 20200352632A1 · Batchelor et al. · 2020 [cited by applicant]
US 20200352635A1 · Batchelor et al. · 2020 [cited by applicant]
US 20200352636A1 · Batchelor et al. · 2020 [cited by applicant]
US 20200352637A1 · Batchelor · 2020 [cited by applicant]
US 20200352638A1 · Batchelor et al. · 2020 [cited by applicant]
US 20200352639A1 · Batchelor et al. · 2020 [cited by applicant]
US 20240024017A1 · Batchelor et al. · 2024 [cited by applicant]
US 20240065747A1 · Batchelor et al. · 2024 [cited by applicant]
US 20240148428A1 · Batchelor et al. · 2024 [cited by applicant]
US 20240156509A1 · Batchelor et al. · 2024 [cited by applicant]
US 20240315756A1 · Batchelor et al. · 2024 [cited by applicant]
US 20240366285A1 · Batchelor · 2024 [cited by applicant]
AU 2020267650 · 2024 [cited by applicant]
AU 2023274234B2 · 2024 [cited by applicant]
CN 102764153 · 2012 [cited by applicant]
CN 104173103A · 2014 [cited by applicant]
CN 106163437 · 2016 [cited by applicant]
CN 107072705 · 2017 [cited by applicant]
CN 107847262 · 2018 [cited by applicant]
CN 108685612 · 2018 [cited by applicant]
CN 109561928 · 2019 [cited by applicant]
CN 113811255A · 2021 [cited by applicant]
CN 113811255B · 2024 [cited by applicant]
CN 118648965 · 2024 [cited by applicant]
CN 118648966 · 2024 [cited by applicant]
CN 118648967 · 2024 [cited by applicant]
CN 118648968 · 2024 [cited by applicant]
CN 118648969 · 2024 [cited by applicant]
CN 118648970 · 2024 [cited by applicant]
CN 118648971 · 2024 [cited by applicant]
CN 118648972 · 2024 [cited by applicant]
CN 118648973 · 2024 [cited by applicant]
EP 1428480A1 · 2004 [cited by applicant]
EP 1472984A1 · 2004 [cited by applicant]
EP 1647234A1 · 2006 [cited by applicant]
EP 1707144A1 · 2006 [cited by applicant]
EP 1715810A1 · 2006 [cited by applicant]
EP 1776929A1 · 2007 [cited by applicant]
EP 1810632A1 · 2007 [cited by applicant]
EP 1810634A1 · 2007 [cited by applicant]
EP 1820460A2 · 2007 [cited by applicant]
EP 1849425A1 · 2007 [cited by applicant]
EP 1862137A1 · 2007 [cited by applicant]
EP 1886636A1 · 2008 [cited by applicant]
EP 1913889A1 · 2008 [cited by applicant]
EP 1943973A1 · 2008 [cited by applicant]
EP 1990019A2 · 2008 [cited by applicant]
EP 2001385A2 · 2008 [cited by applicant]
EP 2033588A1 · 2009 [cited by applicant]
EP 2042116A1 · 2009 [cited by applicant]
EP 2239009A1 · 2010 [cited by applicant]
EP 2249735A1 · 2010 [cited by applicant]
EP 2252227A1 · 2010 [cited by applicant]
EP 2296572A1 · 2011 [cited by applicant]
EP 2307098A1 · 2011 [cited by applicant]
EP 2341835A1 · 2011 [cited by applicant]
EP 2353534A1 · 2011 [cited by applicant]
EP 2417926A1 · 2012 [cited by applicant]
EP 2485670A2 · 2012 [cited by applicant]
EP 2486884A1 · 2012 [cited by applicant]
EP 2510895A1 · 2012 [cited by applicant]
EP 2537479A1 · 2012 [cited by applicant]
EP 2620113A1 · 2013 [cited by applicant]
EP 2709549A1 · 2014 [cited by applicant]
EP 2206472B1 · 2014 [cited by applicant]
EP 2777578A1 · 2014 [cited by applicant]
EP 2853217A1 · 2015 [cited by applicant]
GB 2514100 · 2014 [cited by applicant]
JP 2007319684A · 2007 [cited by applicant]
JP 2022531724A · 2022 [cited by applicant]
JP 7318006B2 · 2023 [cited by applicant]
JP 2023126563 · 2023 [cited by applicant]
KR 20130052534A · 2013 [cited by applicant]
KR 20140138058A · 2014 [cited by applicant]
KR 20160029706 · 2016 [cited by applicant]
KR 102713085 · 2024 [cited by applicant]
NZ 782248 · 2023 [cited by applicant]
WO 2006045090 · 2006 [cited by applicant]
WO 2013158537 · 2013 [cited by applicant]
WO WO2016139872A1 · 2016 [cited by applicant]
WO WO2018020578A1 · 2018 [cited by applicant]
WO WO2020227519A1 · 2020 [cited by applicant]
“U.S. Appl. No. 16/874,042, Corrected Notice of Allowability mailed Oct. 6, 2023”, 3 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,071, Notice of Allowance mailed Sep. 26, 2023”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,145, Response filed Nov. 15, 2023 to Final Office Action mailed Aug. 17, 2023”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,268, Notice of Allowance mailed Oct. 10, 2023”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,268, Supplemental Notice of Allowability mailed Oct. 26, 2023”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,268, Supplemental Notice of Allowability mailed Dec. 13, 2023”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,286, Notice of Allowance mailed Nov. 13, 2023”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,286, Supplemental Notice of Allowability mailed Nov. 22, 2023”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,293, Notice of Allowance mailed Sep. 27, 2023”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,293, Supplemental Notice of Allowability mailed Oct. 12, 2023”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,333, Non Final Office Action mailed Nov. 9, 2023”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,376, Non Final Office Action mailed Sep. 27, 2023”, 17 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,432, Response filed Nov. 1, 2023 to Final Office Action mailed Aug. 2, 2023”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,486, Response filed Dec. 12, 2023 to Non Final Office Action mailed Sep. 14, 2023”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 18/213,086, Preliminary Amendment filed Oct. 11, 2023”, 5 pgs. [cited by applicant]
“U.S. Appl. No. 18/468,916, Preliminary Amendment filed Nov. 14, 2023”, 8 pgs. [cited by applicant]
“Chinese Application Serial No. 202080034752.3, Office Action mailed Sep. 25, 2023”, w/English Translation, 27 pgs. [cited by applicant]
“Korean Application Serial No. 10-2021-7040381, Notice of Preliminary Rejection mailed Nov. 24, 2023”, w/English Translation, 11 pgs. [cited by applicant]
“New Zealand Application Serial No. 782248, Response filed Nov. 6, 2023 to First Examiner Report mailed May 23, 2023”, 13 pgs. [cited by applicant]
“U.S. Appl. No. 18/468,916, Corrected Notice of Allowability mailed Oct. 18, 2024”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,486, Examiner Interview Summary mailed Oct. 22, 2024”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 18/935,060, Preliminary Amendment filed Nov. 4, 2024”, 7 pgs. [cited by applicant]
“Chinese Application Serial No. 202410768472.5 Voluntary Amendment Filed Dec. 17, 2024”, w english claims, 10 pgs. [cited by applicant]
“Japanese Application Serial No. 2023-117341, Notification of Reasons for Rejection mailed Jan. 7, 2025”, W English Translation, 8 pgs. [cited by applicant]
“Singapore Application Serial No. 11202111518W, Written Opinion mailed Jan. 10, 2025”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,486, Notice of Allowance mailed Jan. 29, 2025”, 10 pgs. [cited by applicant]
“European Application Serial No. 20729383.8, Communication Pursuant to Article 94(3) EPC mailed Feb. 7, 2025”, 6 pgs. [cited by applicant]
U.S. Appl. No. 18/776,502, filed Jul. 18, 2024, Short Circuit Error Trapping with Band Between Trigger and Escape Values in Electrosurgical Systems. [cited by applicant]
U.S. Appl. No. 18/734,269, filed Jun. 5, 2024, Terminating Drying Cycles by Monitoring Impedance in Electrosurgical Systems. [cited by applicant]
“U.S. Appl. No. 16/874,042, Final Office Action mailed May 16, 2023”, 15 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,042, Non Final Office Action mailed Nov. 16, 2022”, 15 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,042, Notice of Allowance mailed Aug. 29, 2023”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,042, Preliminary Amendment filed Oct. 14, 2021”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,042, Response filed Feb. 9, 2023 to Non Final Office Action mailed Nov. 16, 2022”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,042, Response filed Jul. 13, 2023 to Final Office Action mailed May 16, 2023”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,071, Final Office Action mailed Mar. 31, 2023”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,071, Non Final Office Action mailed Dec. 20, 2022”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,071, Notice of Allowance mailed Jul. 25, 2023”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,071, Response filed Feb. 10, 2023 to Non Final Office Action mailed Dec. 20, 2022”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,071, Response filed May 22, 2023 to Final Office Action mailed Mar. 31, 2023”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,145, Advisory Action mailed Jan. 25, 2023”, 4 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,145, Advisory Action mailed Dec. 12, 2022”, 3 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,145, Examiner Interview Summary mailed Dec. 21, 2022”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,145, Final Office Action mailed Aug. 17, 2023”, 15 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,145, Final Office Action mailed Sep. 26, 2022”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,145, Non Final Office Action mailed Mar. 31, 2023”, 14 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,145, Non Final Office Action mailed May 10, 2022”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,145, Response filed Jan. 25, 2023 to Advisory Action mailed Dec. 12, 2022”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,145, Response filed Aug. 2, 2023 to Non Final Office Action mailed Mar. 31, 2023”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,145, Response filed Aug. 9, 2022 to Non Final Office Action mailed May 10, 2022”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,145, Response filed Nov. 23, 2022 to Final Office Action mailed Sep. 26, 2022”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,145, Supplemental Amendment filed Dec. 9, 2022 to Final Office Action mailed Sep. 26, 2022”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,185, Corrected Notice of Allowability mailed Jun. 16, 2023”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,185, Non Final Office Action mailed May 9, 2022”, 6 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,185, Non Final Office Action mailed Nov. 28, 2022”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,185, Notice of Allowance mailed Jun. 12, 2023”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,185, Response filed Feb. 9, 2023 to Non Final Office Action mailed Nov. 28, 2022”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,185, Response filed Aug. 9, 2022 to Non Final Office Action mailed May 9, 2022”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,268, Non Final Office Action mailed Apr. 20, 2023”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,268, Non Final Office Action mailed Oct. 17, 2022”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,268, Response filed Jan. 5, 2023 to Non Final Office Action mailed Oct. 17, 2022”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,268, Response filed Jun. 12, 2023 to Non Final Office Action mailed Apr. 20, 2023”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,286, Non Final Office Action mailed May 26, 2023”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,286, Response filed Apr. 27, 2023 to Restriction Requirement mailed Feb. 28, 2023”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,286, Response filed Aug. 2, 2023 to Non Final Office Action mailed May 26, 2023”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,286, Restriction Requirement mailed Feb. 28, 2023”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,293, Final Office Action mailed May 4, 2023”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,293, Non Final Office Action mailed Oct. 6, 2022”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,293, Response filed Jun. 1, 2022 to Restriction Requirement mailed Apr. 1, 2022”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,293, Response filed Jul. 31, 2023 to Final Office Action mailed May 4, 2023”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,293, Response filed Dec. 20, 2022 to Non Final Office Action mailed Oct. 6, 2022”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,293, Restriction Requirement mailed Apr. 1, 2022”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,318, Examiner Interview Summary mailed Feb. 15, 2023”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,318, Final Office Action mailed Jan. 20, 2023”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,318, Non Final Office Action mailed Jul. 15, 2022”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,318, Notice of Allowance mailed Mar. 2, 2023”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,318, Notice of Allowance mailed Jun. 29, 2023”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,318, Response filed Feb. 10, 2023 to Final Office Action mailed Jan. 20, 2023”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,318, Response filed Oct. 10, 2022 Non-Final Office Action mailed Jul. 15, 2022”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,333, Response filed Jul. 31, 2023 to Restriction Requirement mailed Jun. 2, 2023”, 6 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,333, Restriction Requirement mailed Jun. 2, 2023”, 6 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,335, Corrected Notice of Allowability mailed Apr. 19, 2023”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,335, Non Final Office Action mailed Dec. 27, 2022”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,335, Notice of Allowance mailed Mar. 21, 2023”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,335, Response filed Feb. 24, 2023 to Non Final Office Action mailed Dec. 27, 2022”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,376, Advisory Action mailed Mar. 23, 2023”, 4 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,376, Final Office Action mailed Jan. 6, 2023”, 20 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,376, Non Final Office Action mailed Jun. 27, 2022”, 13 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,376, Response filed Feb. 27, 2023 to Final Office Action mailed Jan. 6, 2023”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,376, Response filed May 3, 2023 to Advisory Action mailed Mar. 23, 2023”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,376, Response filed Sep. 27, 2022 to Non Final Office Action mailed Jun. 27, 2022”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,393, Advisory Action mailed May 12, 2023”, 4 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,393, Corrected Notice of Allowability mailed Aug. 4, 2023”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,393, Final Office Action mailed Feb. 14, 2023”, 18 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,393, Non Final Office Action mailed Apr. 8, 2022”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,393, Non Final Office Action mailed Sep. 14, 2022”, 14 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,393, Notice of Allowance mailed Jun. 9, 2023”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,393, Response filed Apr. 14, 2023 to Final Office Action mailed Feb. 14, 2023”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,393, Response filed Jun. 13, 2022 to Non Final Office Action mailed Apr. 8, 2022”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,393, Response filed Nov. 10, 2022 to Non Final Office Action mailed Sep. 14, 2022”, 13 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,432, Final Office Action mailed Aug. 2, 2023”, 17 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,432, Non Final Office Action mailed Jan. 18, 2023”, 17 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,432, Response filed Apr. 17, 2023 to Non Final Office Action mailed Jan. 18, 2023”, 11 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,466, Final Office Action mailed Dec. 2, 2022”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,466, Non Final Office Action mailed Aug. 15, 2022”, 6 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,466, Notice of Allowance mailed Feb. 17, 2023”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,466, Response filed Feb. 1, 2023 to Final Office Action mailed Dec. 2, 2022”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,466, Response filed Sep. 27, 2022 to Non Final Office Action mailed Aug. 15, 2022”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,486, Advisory Action mailed Jun. 20, 2023”, 3 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,486, Final Office Action mailed Apr. 13, 2023”, 17 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,486, Non Final Office Action mailed Sep. 14, 2023”, 20 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,486, Non Final Office Action mailed Oct. 6, 2022”, 17 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,486, Response filed Jan. 5, 2023 to Non Final Office Action mailed Oct. 6, 2022”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,486, Response filed Jun. 8, 2023 to Final Office Action mailed Apr. 13, 2023”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,486, Response filed Jul. 28, 2023 to Advisory Action mailed Jun. 20, 2023”, 12 pgs. [cited by applicant]
“Australian Application Serial No. 2020267650, First Examination Report mailed Nov. 24, 2022”, 3 pgs. [cited by applicant]
“Australian Application Serial No. 2020267650, Response filed Feb. 13, 2023 to First Examination Report mailed Nov. 24, 2022”, 24 pgs. [cited by applicant]
“Australian Application Serial No. 2020267650, Response Filed Jun. 8, 2023 to Subsequent Examiners Report mailed May 23, 2023”, 8 pgs. [cited by applicant]
“Australian Application Serial No. 2020267650, Response filed Aug. 3, 2023 to Subsequent Examiners Report mailed Jul. 6, 2023”, 29 pgs. [cited by applicant]
“Australian Application Serial No. 2020267650, Subsequent Examiners Report mailed Mar. 6, 2023”, 3 pgs. [cited by applicant]
“Australian Application Serial No. 2020267650, Subsequent Examiners Report mailed May 23, 2023”, 3 pgs. [cited by applicant]
“Australian Application Serial No. 2020267650, Subsequent Examiners Report mailed Jul. 6, 2023”, 3 pgs. [cited by applicant]
“Dominican Republic Application Serial No. P2021-0231, Office Action mailed Nov. 15, 2021”, with machine translation, 2 pgs. [cited by applicant]
“International Application Serial No. PCT/US2020/031857, International Preliminary Report on Patentability mailed Nov. 18, 2021”, 19 pgs. [cited by applicant]
“International Application Serial No. PCT/US2020/031857, International Search Report mailed Oct. 20, 2020”, 14 pgs. [cited by applicant]
“International Application Serial No. PCT/US2020/031857, Invitation to Pay Additional Fees mailed Aug. 28, 2020”, 25 pgs. [cited by applicant]
“International Application Serial No. PCT/US2020/031857, Written Opinion mailed Oct. 20, 2020”, 17 pgs. [cited by applicant]
“Japanese Application Serial No. 2021-566238, Notification of Reasons for Refusal mailed Feb. 7, 2023”, w/ English Translation, 15 pgs. [cited by applicant]
“Japanese Application Serial No. 2021-566238, Response filed Jun. 7, 2023 to Notification of Reasons for Refusal mailed Feb. 7, 2023”, with English claims, 10 pgs. [cited by applicant]
“Japanese Application Serial No. 2021-566238, Voluntary Amendment Filed Feb. 3, 2022”, w/English claims, 14 pgs. [cited by applicant]
“New Zealand Application Serial No. 782248, First Examiner Report mailed May 23, 2023”, 8 pgs. [cited by applicant]
“Singaporean Application Serial No. 11202111518W, Response filed Apr. 27, 2022 to Order Letter mailed Oct. 14, 2021”, 26 pgs. [cited by applicant]
U.S. Appl. No. 18/480,072, filed Oct. 3, 2023, Incremental Adjustment of a Control Parameter as a Function of a Monitored Variable in Electrosurgical Systems. [cited by applicant]
U.S. Appl. No. 18/538,054, filed Dec. 13, 2023, Open Circuit Check in Electrosurgical Systems. [cited by applicant]
U.S. Appl. No. 18/480,691, filed Oct. 4, 2023, Pulsing at the End of the Drying Cycle in Electrosurgical Systems. [cited by applicant]
U.S. Appl. No. 18/494,050, filed Oct. 25, 2023, Terminating a Pulse Based Upon Measurements Taken Within the Pulse in Electrosurgical Systems. [cited by applicant]
“U.S. Appl. No. 16/874,432, Non Final Office Action mailed Dec. 20, 2023”, 22 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,376, Response filed Dec. 21, 2023 to Non Final Office Action mailed Sep. 27, 2023”, 11 pgs. [cited by applicant]
“Singapore Application Serial No. 11202111518W. Written Opinion mailed Jan. 15, 2024”, 12 pgs. [cited by applicant]
“Korean Application Serial No. 10-2021-7040381, Response filed Jan. 18, 2024 to Notice of Preliminary Rejection mailed Nov. 24, 2023”, with English claims, 41 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,333, Response filed Jan. 19, 2024 to Non Final Office Action mailed Nov. 9, 2023”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 18/494,050, Preliminary Amendment filed Jan. 24, 2024”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,432, Response filed Jan. 24, 2024 to Non Final Office Action mailed Dec. 20, 2023”, 14 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,145, Non Final Office Action mailed Jan. 25, 2024”, 17 pgs. [cited by applicant]
“U.S. Appl. No. 18/538,054, Preliminary Amendment filed Feb. 2, 2024”, 6 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,071, Corrected Notice of Allowability mailed Feb. 9, 2024”, 4 pgs. [cited by applicant]
“Chinese Application Serial No. 202080034752.3, Response filed Feb. 18, 2024 to Office Action mailed Sep. 25, 2023”, w English Claims, 16 pgs. [cited by applicant]
“U.S. Appl. No. 16/874,486, Final Office Action mailed Mar. 27, 2024”, 21 pgs. [cited by applicant]
Cited By (1)
US 12,714,489